I am pleased to invite you to participate in the 1st Annual BCAN Immuno-oncology Intensive Workshop, titled “Getting on Board with Novel Therapies: Key Issues for the Advanced Bladder Cancer Clinic Team.”

For more than three decades, systemic platinum-based chemotherapy has been the standard first-line treatment for patients with inoperable or advanced metastatic bladder cancer (mBC). Unfortunately, the duration of response is short-lived. As one of the first malignancies whereby immunotherapy demonstrated efficacy, nearly forty years ago with the intravesical administration of the Mycobacterium bovis-derived Bacillus Calmette-Guérin (BCG), mBC has now been shown to be susceptible to systemic immunotherapy in the form of immune checkpoint inhibitors (ICIs). In addition to robust and exciting efficacy outcomes, ICIs have demonstrated well-tolerated safety profiles, especially in comparison to traditional platinum-based chemotherapy regimens. Beyond currently-approved first and second line indications for ICIs in mBC, these agents are also being studied across the disease-continuum, from high risk NMIBC patients who are BCG-unresponsive to neoadjuvant modalities in MIBC, all of which constitute areas of keen interest to community-based urologists dedicated to advanced bladder cancer care and management.

This half-day, multi-accredited educational activity will focus on key issues of importance to you and your clinical team, concentrating on the implementation of IO for dedicated community urology practices desiring to establish excellence of care.

Lecture topics include:

  • Traditional Therapies in the Bladder Cancer Treatment Landscape
  • How Immunotherapy is Changing the Game in Bladder Cancer Management
  • Case Studies focused on the role of the interprofessional team, and effective management of immune-related adverse events
  • Practical aspects for using immune checkpoint inhibitors in the community setting
  • For patients with BCG-unresponsive, high risk NMIBC, as well as advanced/metastatic bladder cancer, there exists a substantial unmet educational need to bring training to the medical practices within the communities where the significant majority of patients are diagnosed, evaluated, and managed.

    I hope that you can join us in Washington, DC this spring for this half-day workshop.


    Neal Shore, MD